PTPI (Petros Pharmaceuticals Inc) Net Profit

Corporate emblem and logo of petrospharma.com (PTPI)

The annual financial result of Petros Pharmaceuticals (PTPI) is based on marketing efficiency and the availability of prescription drugs, with the 0.00 mark recording this indicator. High patent barriers and FDA controls limit competitor entry. A steady cash flow is ensured by the inertia of prescriptions for men's health drugs, which supports the company's current operational momentum.

PTPI (Petros Pharmaceuticals, Inc.) Company Net Income history from 07/04/2022 to 06/28/2025

Financial and market metric breakdowns for Petros Pharmaceuticals, Inc. (PTPI)

- price and consensus price forecast:
Stock Quotes Petros Pharma|PTPI - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Petros Pharma|PTPI - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Petros Pharmaceuticals|PTPI - Company Book Value|Market-to-Book Ratio petrospharma.com|PTPI - Cumulative Company Assets
- debt and solvency information:
Aggregate Debt to Capital Petros Pharmaceuticals|PTPI - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Petros Pharmaceuticals Inc|PTPI - Company Aggregate Debts|Debts to Book Value Petros Pharma|PTPI - Company Long-Term Debt|Company Short-Term Loans and Borrowings Petros Pharmaceuticals|Critical Liquidity Ratio petrospharma.com
- net income and valuation multiples indicators:
PTPI - Net Profit
Fundamental valuation:PTPI Petros Pharma
Flagship merchandise of Petros Pharmaceuticals Inc

This indicator measures net daily return adjusted for accounting distortions, allowing for an assessment of the real efficiency of the operating cycle and the impact of macroeconomics on capitalization. By analyzing the annual financial results of Petros Pharmaceuticals (PTPI), an investor can see how the commercialization of men's health drugs converts into profit, determining the business resilience of Petros Pharmaceuticals (PTPI) within a narrow therapeutic segment.

Main competitors

Net Income Haleon Corp|KVUE (Kenvue Inc.) - Net Profit|Net Profit veronapharma.com|Net Income MENS (Jyong Biotech)|LGND (Ligand Pharmaceuticals Incorporated) - Final Profit|Company Net Income Amneal Pharmaceuticals Inc AMRX|Perrigo Corp (PRGO) - Company Net Income|ALVO: Net Income|liquidia.com - Profit After Payment of Taxes|GLPG: Net Profit|ANI Pharmaceuticals Inc - Final Profit|MNKD (MannKind Corp.) - Net Profit|Company Net Income Amphastar Corp AMPH|Company Net Income Pacira BioSciences (PCRX)|SPRY (ars-pharma.com) - Final Profit|Company Net Income Theravance Biopharma, Inc. TBPH|AQST (Aquestive Therapeutics Inc) - Profit After Tax|scPharma - Net Profit|Company Net Income Tectonic Therapeutic, Inc.|TNXP (Tonix Pharmaceuticals) - Net Income|SXTC: Profit After Payment of Taxes|Company Net Income Eupraxia Pharmaceuticals, Inc.|BHST: Final Profit|Company Net Income Invizyne Technologies, Inc. (EXOZ)|ORMP - Company Net Income|Company Net Income Entera Bio ENTX|Net Financial Result ipatherapeutics.com (HYFT)|ABVC: Net Income|Final Profit CPIX (Cumberland Pharmaceuticals Inc)|Quantum BioPharma Limited (QNTM) - Company Net Income|Profit After Tax FGEN (FibroGen Corporation)|TELO (Telomir Pharmaceuticals) - Net Profit|RANI: Final Profit|Net Profit SNYR|Net Profit rallybio.com (RLYB)|Company Net Income Lexaria Bioscience Corp. LEXX|Final Profit PULM|PTHL - Company Net Income|Aptorum Group Limited (APM) - Net Income|LYRA: Net Profit|impactbiomedinc.com (IBO) - Net Profit|TNFA (TNF Pharmaceuticals Inc.) - Net Profit|Net Income cbdMD Corp (YCBD)|Net Profit PRFX|CYTO - Company Net Income|Lipella Pharmaceuticals, Inc. - Net Income|Net Profit OptiNose Inc OPTN|PIRS: Net Income|Procaps Group Corp - Profit After Payment of Taxes|QLI: Net Profit|SLRN - Net Financial Result|TFFP (TFF Pharmaceuticals, Inc.) - Net Profit